Troutman Pepper Locke senior associate Ryan Last explains when markets will start to significantly react to the upcoming pharma tariffs. In April of this year, President Trump announced plans to ...
It was a jarring experience that stemmed from a startlingly common misconception: that adults don't get T1D; however, she is ...
Zymeworks will pay $17.00/share (~$929M) for Theravance, prioritizing Yupelri-linked profitability and planned post-close ...
FDA’s PreCheck Pilot Program aims to de-risk and accelerate domestic capacity buildouts via earlier regulatory interaction, aligning manufacturing policy with supply-chain resilience priorities.
Pharmaceutical Executive: How will targeted onshoring impact pharma’s domestic manufacturing? Ryan Last: Targeted reshoring ...
In today's Pharmaceutical Executive Daily, AbbVie announces a $10.9 billion agreement to acquire Apogee Therapeutics, adding ...
QuantumCell received worldwide rights to NeuroRestore/ACD856, with closing contingent on foreign direct investment approvals in Sweden and Denmark under customary regulatory conditions. Financial ...
Resilient field models emphasize continuous territory coverage via agile deployment, blending scalable virtual reach with ...
In today's Pharmaceutical Executive Daily, the FDA approves Gilead's Trodelvy for the first-line treatment of metastatic ...
In today's Pharmaceutical Executive Daily, a pharma M&A roundup covers Ipsen's up to $1.75 billion acquisition of Kartos Therapeutics and Zymeworks' $929 million acquisition of Theravance Biopharma, ...
Medicare GLP-1 Bridge provides Wegovy to eligible beneficiaries for $50/month through 2027, creating a defined access channel for obesity treatment previously largely excluded from Medicare coverage.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results